Power driven tunable white upconversion luminescence from Lu2TeO6 tri-doped with Yb3+, Tm3+ and Ho3+

Tunable power driven white upconversion luminescence was realized in the Yb³⁺, Tm³⁺, and Ho³⁺ tri-doped Lu₂TeO₆.

Modeling the effects of point and non-point source pollution on a diversion channel from Yellow River to an artificial lake in China

The Dragon lake diversion channel (DLDC) is the only river that recharges Dragon Lake, an artificial lake in China. This paper examines the main factors influencing water quality by investigating point source and non-point source pollutants along the main route. Based on the complicated system of rivers and desilting basins, a three-dimensional water quality model using environmental fluid dynamics code (EFDC) was developed. The model of DLDC was calibrated and verified using observed data. The error ranges of river water level, total phosphorus, total nitrogen and chemical oxygen demand were within 5%, 10%, 16% and 20%, respectively, all of which meet the precision requirement. The model was employed to predict the concentrations of pollutants in the main stream under current pollution loads within a year and a flood lasting for 24 hours. The results revealed that the main pollution sources that influence the water quality of waterways were the point sources followed by the non-point pollution sources. Water quality improved when large water quantities were delivered and this trend can be described as dilution. The water quality of the Dongfeng main channel meets the requirement; however, the water quality of the Dongfeng River is somewhat poor, and the water quality of the Wei River is seriously contaminated. To address these problems, we suggest that the Dongfeng River and Wei River adopt a culvert under its riverbeds.

Monoclonal antibody-related drugs for cancer therapy

Much progress has been made during the last few decades in the treatment of malignancies. Many types of cancer cells comprising the tumor mass carry molecular markers that are not expressed or are expressed at much lower levels in normal cells. These findings provide new leads to drug design and development of therapeutic strategies involving monoclonal antibodies (mAbs) or related antibody drugs to treat malignancies. This article reviews recent advances in this targeting approach with a focus on the evolution and current use of prospective antibody drugs as effective ways to treat cancer. Additionally, the development of prospective antibody-drug conjugates will also be briefly described.